209 related articles for article (PubMed ID: 1815760)
1. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
Mezzanzanica D; Canevari S; Colnaghi MI
Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
[TBL] [Abstract][Full Text] [Related]
2. Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.
Mezzanzanica D; Garrido MA; Neblock DS; Daddona PE; Andrew SM; Zurawski VR; Segal DM; Wunderlich JR
Cancer Res; 1991 Oct; 51(20):5716-21. PubMed ID: 1833054
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
5. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.
Mezzanzanica D; Canevari S; Ménard S; Pupa SM; Tagliabue E; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Apr; 41(4):609-15. PubMed ID: 3258590
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
[TBL] [Abstract][Full Text] [Related]
7. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
8. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
9. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.
Molthoff CF; Buist MR; Kenemans P; Pinedo HM; Boven E
J Nucl Med; 1992 Nov; 33(11):2000-5. PubMed ID: 1432162
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
Negri DR; Tosi E; Valota O; Ferrini S; Cambiaggi A; Sforzini S; Silvani A; Ruffini PA; Colnaghi MI; Canevari S
Br J Cancer; 1995 Oct; 72(4):928-33. PubMed ID: 7547242
[TBL] [Abstract][Full Text] [Related]
11. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
[TBL] [Abstract][Full Text] [Related]
12. Purification of bispecific F(ab')2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer.
Warnaar SO; De Paus V; Lardenoije R; Machielse BN; De Graaf J; Bregonje M; Van Haarlem H
Hybridoma; 1994 Dec; 13(6):519-26. PubMed ID: 7737675
[TBL] [Abstract][Full Text] [Related]
13. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
[TBL] [Abstract][Full Text] [Related]
14. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
15. Localization of radiolabelled F(ab')2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts.
Moseley KR; Battaile A; Knapp RC; Haisma HJ
Int J Cancer; 1988 Sep; 42(3):368-72. PubMed ID: 3417365
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients.
Tibben JG; Boerman OC; Massuger LF; Schijf CP; Claessens RA; Corstens FH
Int J Cancer; 1996 May; 66(4):477-83. PubMed ID: 8635863
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
18. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
20. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]